Ann: Update on Capital Raising, page-2

The capital raising:
- is being conducted at a price of 3 cents per share;
- is an excluded offer available to professional investors only and will introduce new
sophisticated and institutional investors to Phylogica’s register;
- is being supported by the Company’s existing major shareholders; and
- will provide funding for three primary activities:
o Completing the screening of PYC’s enriched drug libraries for ‘second
generation’ Cell Penetrating Peptides (CPPs);
o Reaching a definitive read-out on the ability of PYC’s CPPs to deliver a range of
different therapeutic cargoes in therapeutic settings (either ex vivo or in vivo);
and
o Advancing its flagship program through to an Investigational New Drug (IND)
filing in order to enable ‘first in human’ studies utilising the company’s CPPs.
The company expects to finalise the raising and resume normal trading prior to the end of this
week.
Phylogica (ASXYC) is the owner of a peptide library containing the extraordinary richness and
diversity of nature. We are using these libraries to develop a drug delivery platform capable of
reaching the highest value drug targets located inside cells. Our delivery platform enables drug
cargoes to cross the cell membrane and directly reach their target.